Patients with MM that is refractory to (proteasome inhibitors) PIs, (immunomodulatory drugs) IMiDs or anti-CD38 mAb therapies remain in very serious condition with significant co-morbidities undermining quality of life and resulting in poor overall survival (OS). This evidence concerns the gene CD38 and Miyoshi myopathy.